Skip to main content

Improving End-of-Life Care for Patients With Acute Myeloid Leukemia Receiving Non-Curative Therapy: Richa Thakur, MD

Oncology Data Advisor® · Improving End-of-Life Care for Patients With AML Receiving Non-Curative Therapy: Richa Thakur, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Dr. Richa Thakur, OncData Fellows Forum member and Hematology/Oncology Fellow at Northwell Health, discusses her poster presentation on end-of-life outcomes in patients with acute myeloid leukemia (AML) receiving non-curative chemotherapy. Dr. Thakur shares her passion for improving pa...

Continue reading

Improving Quality of Life in Multiple Myeloma Through Bortezomib Dose Reduction With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD

At the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Rahul Banerjee, Editor in Chief of Oncology Data Advisor, sat down with Dr. Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas (UT) Southwestern Medical Center, to discuss their abstract about real-world dosing and prescribing patterns of bortezomib in newly diagnosed multiple myeloma. Dr. Banerjee and Dr. Kaur debate the pros and cons of once- versus twice-weekly dosing of bortezomib, its impact on tolerability and outcomes, and changes in trial design that are needed to make once-weekly dosing a new standard in clinical practice.  

Continue reading
Tags:

Real-World Outcomes of Brexucabtagene Autoleucel for B-Cell ALL With Evandro Bezerra, MD

Oncology Data Advisor® · Real-World Outcomes of Brexuctabtagene Autoleucel for B-Cell ALL: Evandro Bezerra, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Evandro Bezerra, a Hematology Specialist at the Ohio State University Comprehensive Cancer Center, sat down with Oncology Data Advisor to discuss his team's research regarding real-world outcomes of brexucabtagene autoleucel (brexu-cel) for B-cell acute lymphoblastic leukemia (ALL).   Oncology Data...

Continue reading

Improving Diversity in Multiple Myeloma Clinical Trials With Craig Cole, MD

At the recent American Society of Hematology (ASH) Annual Meeting, Craig Cole, MD, Assistant Professor at Karmanos Cancer Institute, sat down with Oncology Data Advisor to share his passion for improving diversity in multiple myeloma clinical trials. He discusses the efforts that are currently underway to increase diverse accrual and the importance of raising awareness in order to address this issue both within the community and on a global scale.  

Continue reading

Investigating Talquetamab Plus Pomalidomide in the MonumenTAL-2 Study With Jeffrey Matous, MD

Oncology Data Advisor® · Investigating Talquetamab + Pomalidomide in the MonumenTAL-2 Study: Jeffrey Matous, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Jeffrey Matous, MD, a Member of the Colorado Blood Cancer Institute in Denver, Colorado, presented his team's research and results of the MonumenTAL-2 trial, which studied talquetamab plus pomalidomide in patients with relapsed/refractory multiple myeloma. Dr. Matous then sat down with Oncology Data Advis...

Continue reading

Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes With Claire Saxton, MBA

At the 2023 American Society of Hematology (ASH) Annual Meeting, Claire Saxton, Executive Vice President of Insights and Impact at Cancer Support Community, presented her team's study on communication that enables shared decision making in myelodysplastic syndromes (MDS). While there, she sat down with Oncology Data Advisor to discuss more about the results of the study and ways that health care professionals and patient advocacy groups can partner to ensure that clear and consistent messages are being delivered to patients with MDS so that they can be more informed and involved in their care.  

Continue reading

Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD

Oncology Data Advisor® · Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD   At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Brittany Ragon, Adult Leukemia and Transplant Specialist at Levine Cancer Institute, sat down with Oncology Data Advisor to discuss her presentation on neighborhood disadvantages associated with inferior overall survival outcomes for patients with acute myeloid leukemia (AML). In additio...

Continue reading

Navigating the Residency and Fellowship Experience by Creating Opportunities in Oncology With Waqas Haque, MD

Oncology Data Advisor® · Navigating the Fellowship Experience by Creating Opportunities in Oncology With Waqas Haque In this Oncology Data Advisor® Fellows Forum interview, member Waqas Haque, MD, an Internal Medicine Resident at New York University, shares his medical training journey, the research he has conducted as Clinical Investigator Track Resident, his plans for applying to an oncology fellowship, advice for navigating the experience, tips for acquiring oncology exposure durin...

Continue reading

Approval of Capivasertib for PIK3CA/AKT1/PTEN–Altered Breast Cancer With Jason Mouabbi, MD, and Carlos Doti, MD

Recently, the FDA granted approval to capivasertib in combination with fulvestrant for patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations. In this interview, Editorial Board member Dr. Jason Mouabbi speaks with Dr. Carlos Doti, Head of Medical Affairs, US Oncology at AstraZeneca, about the significance of the approval, its dosing schedule, AstraZeneca's approach towards patient education and adverse event management, and the future of capivasertib in different treatment settings.  

Continue reading

CLL Society: Paving the Way for CLL Patients and Survivors With Brian Koffman, MD

CLL Society is a patient-centric, physician-curated nonprofit organization that prioritizes patient education, advocacy, and research for the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) community. Dr. Brian Koffman co-founded the organization after being diagnosed with CLL in 2005, and he currently serves as Executive Vice President and Chief Medical Officer. He recently attended the American Society of Hematology (ASH) Annual Meeting to acquire the latest CLL research to bring back and disseminate to patients, and while there, he sat down with Oncology Data Advisor to share more about the educational and advocacy work that the society does, updates in CLL research being presented at the meeting, and how patients with CLL can become more involved and empowered in their treatment and care.  

Continue reading

Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting With David Andorsky, MD

Oncology Data Advisor® · Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented his research and observations regarding patterns of care with Bruton tyrosine kinase (BTK) inhibitors and the distribution of social determinants of h...

Continue reading

Exploring Results of the IsKia Trial in Newly Diagnosed Multiple Myeloma With Annemiek Broijl, MD, PhD

In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Annemiek Broijl, Hematologist at Erasmus MC Cancer Institute in the Netherlands, discusses the IsKia trial, of which she is the Co-Primary Investigator, and its unique primary end point of measurable residual disease (MRD).  

Continue reading

Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes With Christopher Su, MD

Oncology Data Advisor® · Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes: Christopher Su, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Christopher Su, MD, a Hematologist at the Fred Hutchinson Cancer Center, presented his research regarding financial hardships experienced in the transplant setting for myelodysplastic syndromes (MDS). Dr. Su then set down with Oncology Data Advisor to further discuss his study, the res...

Continue reading

Coping With Psychological Distress Prior to Hematopoietic Cell Transplantation With Richard Newcomb, MD

Patients with hematologic malignancies undergoing hospitalization for hematopoietic cell transplantation experience significant psychological distress, and they cope in different ways. In this interview from the 2023 American Society of Hematology (ASH), Dr. Richard Newcomb, Instructor of Medicine at Harvard Medical School, discusses his presentation on coping mechanisms employed by patients who are preparing for transplantation and ways that health care providers can help support their patients during this time.  

Continue reading

Investigating CD19-Targeted CAR T Cells for Autoimmune Diseases: Fabian Mueller, MD

Oncology Data Advisor® · Investigating CD19-Targeted CAR T Cells for Autoimmune Diseases: Fabian Mueller, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Fabian Mueller, the Principal Investigator at the Laboratory of Molecular Immunotherapeutics (LMIT) at the University Hospital of Erlangen, in Germany, about his study which investigated CD19-targeted CAR T cells for refractory systemic autoimmune diseases.   O...

Continue reading

Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan, MBBS, MHS

Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In this interview, Dr. Zeidan further delves into his research and what it could mean for the future treatment landscape of MD...

Continue reading

Lowering Talquetamab Dosing Intensity to Improve Tolerability With Ajai Chari, MD

Oncology Data Advisor® · Lowering Talquetamab Dosing Intensity to Improve Tolerability: Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, Director of the Myeloma Program at the University of California, San Francisco, sat down with Oncology Data Advisor to discuss his abstract and presentation regarding updated results from the MonumenTAL-1 study and what to look forward to from the ever-evolving treatment landscape of multiple myeloma. ...

Continue reading

Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan, MBBS, MHS

Oncology Data Advisor® · Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In thi...

Continue reading

Maintaining Functioning and Quality of Life With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD

Oncology Data Advisor® · Maintaining Functioning and QOL With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Benoit Tessoulin, MD, PhD, Head of the Lymphoma Department at the Nantes University Hospital in France, sat down with Oncology Data Advisor to discuss the results from the ELM-2 study in which the efficacy of odronextamab was investigated for maintaining functionality and quality of life in patients ...

Continue reading

Advancing Inclusion for Blood Donation Systems for Marginalized Groups With Warren Fingrut, MD

Oncology Data Advisor® · Advancing Inclusion for Blood Donation Systems for Marginalized Groups: Warren Fingrut, MD At the recent American Society of Hematology (ASH) Annual Meeting, Warren Fingrut, MD, a Transplant and Cell Therapy Physician at MD Anderson Cancer Center and Founder and Director of Stem Cell Club, a donor recruitment organization based in Canada, sat down with Oncology Data Advisor to discuss his team's research and presentation addressing disparities experienced by m...

Continue reading